[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxAdpR9hPVHzW6PufHuzlK8MXfr7Wa8TDFNB1gIXAsDM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"IRCCS Centro Neurolesi Bonino Pulejo",[4],66,false,26,0,6489,2,63,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Parkinson Disease",11,{"name":18,"count":19},"Stroke",8,{"name":21,"count":19},"Multiple Sclerosis",{"name":23,"count":24},"Autism Spectrum Disorder",5,{"name":26,"count":27},"Mild Cognitive Impairment (MCI)",3,{"name":29,"count":27},"Neurologic Disorder",{"name":31,"count":27},"Alzheimer Disease",{"name":33,"count":27},"Dementia",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07360977","Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)","2026-05-19","bioactivated GRA for adult patients",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,74,92,118],{"intervention":39,"totalTrials":49,"cells":50},1,{"EARLY_PHASE1":51,"PHASE1":53,"PHASE2":55,"PHASE3":57,"PHASE4":59,"NA":61},{"trials":52,"activeCount":9},[],{"trials":54,"activeCount":9},[],{"trials":56,"activeCount":9},[],{"trials":58,"activeCount":9},[],{"trials":60,"activeCount":9},[],{"trials":62,"activeCount":49,"soonestReadout":38},[63],{"nctId":36,"briefTitle":37,"status":64,"phases":65,"primaryCompletion":38,"completion":38,"start":66,"enrollment":67,"conditions":68,"interventions":72},"RECRUITING",[46],"2026-01",300,[69,70,71],"PARKINSON DISEASE (Disorder)","Multiple Sclerosis (MS) - Relapsing-remitting","Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases",[39,73],"bioactivated GRA for pediatric patients",{"intervention":73,"totalTrials":49,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":86},{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"trials":81,"activeCount":9},[],{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":9},[],{"trials":87,"activeCount":49,"soonestReadout":38},[88],{"nctId":36,"briefTitle":37,"status":64,"phases":89,"primaryCompletion":38,"completion":38,"start":66,"enrollment":67,"conditions":90,"interventions":91},[46],[69,70,71],[39,73],{"intervention":93,"totalTrials":49,"cells":94},"Dimethyl Fumarate 240 MG [Tecfidera]",{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":105},{"trials":96,"activeCount":9},[],{"trials":98,"activeCount":9},[],{"trials":100,"activeCount":9},[],{"trials":102,"activeCount":9},[],{"trials":104,"activeCount":9},[],{"trials":106,"activeCount":9},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"NCT05811949","Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.","COMPLETED",[],"2022-10-11","2023-06-07","2021-02-24",52,[21],[93],{"intervention":119,"totalTrials":49,"cells":120},"Sativex",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":131},{"trials":122,"activeCount":9},[],{"trials":124,"activeCount":9},[],{"trials":126,"activeCount":9},[],{"trials":128,"activeCount":9},[],{"trials":130,"activeCount":9},[],{"trials":132,"activeCount":9},[133],{"nctId":134,"briefTitle":135,"status":110,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT03186664","The Role of SAtivex® in Robotic-Rehabilitation",[46],"2017-12","2018-06","2016-12-28",40,[142],"Rehabilitation",[119]]